Catto - Figure 35
Intermediate risk NMI: Follow-up
FIG. 35: The NICE recommends offering patients with intermediate-risk bladder cancer follow-up at 3, 9, and 18 months, and then once a year thereafter.[27] They can be considered for discharge after 5 years, especially if they have competing mortality and morbidity, and because it is becoming less likely to offer radical treatment if they experience deterioration.
References
[27]
National Institute for Health and Care Excellence (NICE). Bladder cancer: diagnosis and management: NICE guideline [NG2]. London, UK: NICE; 2015 https://www.nice.org.uk/guidance/ng2 Accessed July 22, 2017
